EWA
TXG icon

EP Wealth Advisors’s 10x Genomics TXG Stock Holding History

EP Wealth Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$382K Buy
18,007
+6,501
+57% +$130K ﹤0.01% 1032
2025
Q4 		$188K Buy
+11,506
New +$174K ﹤0.01% 1401

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EP Wealth Advisors's TXG Position: Q1 2026 in Review

EP Wealth Advisors increased its 10x Genomics (TXG) stake by 57% in Q1 2026, buying an estimated $130K and bringing the position to 18,007 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #1032.

EP Wealth Advisors first reported a position in TXG in Q4 2025 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • EP Wealth Advisors held 18,007 shares of 10x Genomics worth $382K as of Q1 2026.
  • EP Wealth Advisors bought 6,501 10x Genomics shares in Q1 2026, an estimated $130K.
  • 10x Genomics made up ﹤0.01% of EP Wealth Advisors's portfolio in Q1 2026, its #1032 holding.
  • EP Wealth Advisors first reported a position in 10x Genomics in Q4 2025 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.